Open Day at ISAE-SUPAERO!
20.9.2019 12:53:00 EEST | Business Wire | Press release
As part of the Science Festival, this year organized on the theme of “Talking about Science, Imagining the Future”, ISAE-SUPAERO will open up its entire campus to the public on Saturday, October 12th from 10 am to 6 pm. Intended for families, companies, partners, journalists and alumni, this event should bring in over 3,000 attendees, as was the case in the three previous years!
The program for the day includes many opportunities to discover science today and our vision of the science of the future, with the challenges this entails for the future of our planet.
On the program:
➢ Visits to the laboratories and research departments with flight simulators
➢ Visit to the aeroacoustic wind tunnel, unique in Europe,
➢ Demonstrations: how to fly an airplane, Enoskelet, augmented humans, aeroelasticity, drones, use of the gyroscopic effect in space systems, piezoelectric effect, lasers for communicating at the speed of light on Earth and in space, the infinitely small in 3D, Robot Firefighter Game, experimental rockets, Artificial Intelligence, Blockchain, image sensors, an eye on the world,
➢ Meetings with student clubs
➢ Meetings with ISAE-SUPAERO start-ups
➢ Exhibitions
➢ Presentation of digital learning and solutions in digital education innovation<
➢ Information stands on training programs, the ISAE-SUPAERO Foundation, the OSE l’ISAE-SUPAERO diversity program, Erasmus program, the ISAE Group, Alumni Association, Aéroscopia,
➢ Activities for children
➢ Conference “But why does this plane fly safely?”,
➢ Guided tours of the campus, sports facilities, dorms and cafeteria,
➢ Students Shop
➢ Music by the student band, Los Soupaéros
➢ Toulouse’s little tourist train will be there to get around campus easily.
Practical information
Free admission
Address: 10 avenue Edouard Belin 31055 Toulouse. Rocade exit 20.
No parking nearby, use public transport (buses Nos. 27 and 37, Laas CNRS or SUPAERO stop, Faculté de Pharmacie Metro stop)
ID required
Entrance on Avenue Colonel Roche or Avenue Edouard Belin –VélôToulouse stations nearby
Food and drinks area on site
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190920005175/en/
Contact information
Press Contacts:
ISAE-SUPAERO:
Charline Kohler
charlinek@oxygen-rp.com
Tel.: +33 5 32 11 07 32
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces filing of registration statement for proposed initial public offering8.6.2026 14:20:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, announces today that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol “BSP.” Goldman Sachs International, J.P. Morgan, and Allen & Company LLC are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities, BofA Securities, Jefferies, Evercore ISI, BNP Paribas, Mizuho, Societe Generale, Crédit Agricole CIB, IMI – Intesa Sanpaolo, UniCredit, and Banca Akros – Gruppo Banco BPM are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other condit
Xsolla to Attend SuperReturn International 2026 to Advance Strategic Partnerships and Expand Its Presence in Global Private Capital8.6.2026 14:15:00 EEST | Press release
Xsolla, a global leader in video game commerce, today announced its participation in SuperReturn International 2026, taking place June 8–12 at the InterContinental Berlin. Uniting more than 6,000 senior attendees, including 2,000+ LPs and 3,000 GPs, SuperReturn International is widely recognized as the capital of private capital with the best investment opportunities globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260607269536/en/ Graphic: Xsolla The video game industry has matured into one of the largest and most resilient segments of the global entertainment economy, outpacing film and music combined, driving continuous growth through shifting market cycles. Yet the infrastructure powering how games are sold, monetized, and distributed worldwide remains under-examined by much of the institutional investment community. Xsolla's presence at SuperReturn International reflects a broader moment: the convergence of a mu
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release
Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release
Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom